CrushSCI.com
141.1平均天数
125中位天数
53最短天数
274最长天数
3502025发文量

Paper Review Records

全部论文审稿周期

19 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接

169 天

Plain language summary of subcutaneous vs IV amivantamab plus lazertinib in EGFR -altered non-small-cell lung cancer

作者
Natasha B. Leighl; Antonio Passaro; Hiroaki Akamatsu; Alexander I. Spira; Danny Nguyen; Angel Qin; Julia Schuchard; Mohamed Gamil; Mahadi Baig; Mariam Alexander展开收起
作者单位
1. aPrincess Margaret Cancer Centre, Toronto, ON, Canada; 2. bDivision of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy; 3. cInternal Medicine III, Wakayama Medical University, Wakayama, Japan; 4. dVirginia Cancer Specialists, Fairfax, VA, USA; 5. eCity of Hope National Medical Center, Duarte, CA, USA; 6. fUniversity of Michigan Rogel Cancer Center, Ann Arbor, MI, USA; 7. gJohnson & Johnson, Horsham, PA, USA; 8. hJohnson & Johnson, Spring House, PA, USA; 9. iJohnson & Johnson, Raritan, NJ, USA; 10. jHollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA展开收起
PDF源文件 DOI 网页
62 天

Cancer control after pausing treatment with larotrectinib in responding children with sarcoma and a TRK fusion: a plain language summary

作者
Leo Mascarenhas; Christopher Ollis; Yuvraj Singh; Linet Menachery; Domnita-Ileana Burcoveanu; Esther De La Cuesta; Cornelis M van Tilburg; Theodore W Laetsch展开收起
作者单位
1. aGuerin Children’s and Cedars-Sinai Cancer, Cedars-Sinai Health Sciences University, Los Angeles, CA, USA; 2. bPatient author; 3. cValley Springs, CA, USA; 4. dCaregiver author, Gurugram, Haryana, India; 5. eCaregiver author, White Plains, NY, USA; 6. fBayer HealthCare Pharmaceuticals, Inc, Basel, Switzerland; 7. gBayer HealthCare Pharmaceuticals, Inc, Whippany, NJ, USA; 8. hHopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg, Germany; 9. iClinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany; 10. jHeidelberg University, Heidelberg Faculty of Medicine, Department of Pediatric Oncology, Hematology, Immunology, and Pulmonology, Heidelberg University Hospital, Heidelberg, Germany; 11. kNational Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany; 12. lChildren’s Hospital of Philadelphia / University of Pennsylvania, Philadelphia, PA, USA展开收起
PDF源文件 DOI 网页
163 天

Prognostic disparities between radioactive iodine-refractory and non-refractory DTC patients: a cohort study on survival rates and independent risk factors

作者
Menghua Xia; Weifu Lv; Wei Zhao; Liqin Bi; Xueran Guo; Mengxia Zhang; Liangping Shi展开收起
作者单位
1. The First Affiliated Hospital of University of Science and Technology of China (USTC), Division of Life Sciences and Medicine, University of Science and Technology of China展开收起
PDF源文件 DOI 网页
183 天

Smoldering multiple myeloma: a multi-country mixed-methods study on disease perceptions and patient treatment preferences

作者
Matthew Quaife; Cecilia Jimenez-Moreno; Blanca Gros Otero; Aisha Asra; Niodita Gupta-Werner; Katharine S. Gries; Marie-Kristin Leisten; Kathryn Matt; Robin Carson; Robyn Dennis; Jianming He; Bennett Levitan; Sacheeta Bathija展开收起
作者单位
1. Evidera; 2. Johnson & Johnson展开收起
PDF源文件 DOI 网页
196 天

Clinical and genetic risk factors for anthracycline‑induced cardiotoxicity in Chinese early‑stage breast cancer patients: a candidate gene study

作者
Shan Xu; Hao Yang; Nan Hu展开收起
作者单位
1. The Third Affiliated Hospital of Nanjing Medical University; 2. The Third Affiliated Hospital of Soochow University展开收起
PDF源文件 DOI 网页
239 天

A pragmatic adaptation of the RANO clinical risk score for IDH-Wildtype glioblastoma in the absence of MGMT promoter methylation testing

作者
İmdat Eroğlu; Sıla Soylu Koçoğlu; Eron Merovci; Gözde Savaş; Fatih Gürler; Osman Sutcuoglu; Ugur Coskun; Aytug Uner; Murat Ucar; Burak Karaarslan; Ahmet Özet; Nuriye Özdemir; Ozan Yazıcı展开收起
作者单位
1. Gazi University School of Medicine展开收起
PDF源文件 DOI 网页

Expert Matching · Case Demo

把投稿要求,转成可验证的期刊方案

说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。

我们会在半小时内回复。

CrushSCI 在线

客户询问

我是环境工程专业,需要一篇 SCI,希望 3 个月内见刊。没有基金,也没有大牛挂名,可以投哪些期刊?

CrushSCI回复

可以。先按 90 天时限做可行性筛选,同步查找无基金、无知名作者挂靠的典型论文案例,作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议
《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》

样本口径2026 年最近 5 篇有效论文样本

平均审稿59.6 天

中位数65 天

Contact CrushSCI

联系 CrushSCI

留下手机号或微信号,我们将与你确认学术润色、结构优化或一对一辅导咨询需求。

我们会在半小时内回复。

当前选择:学术咨询服务

预留联系方式

也可以直接发送邮件至 leader@crushsci.com

手机号和微信号至少填写一项,仅用于本次咨询联系,不会公开。